Antag Therapeutics
biotech · Copenhagen, DK
Copenhagen biopharma developing a GIPR antagonist for obesity.
Funding history
| Date | Round | Amount |
|---|
| Dec 2024 | Series A Antag Therapeutics raised an €80M Series A led by Versant Ventures to advance clinical development of its GIPR antagonist obesity therapy. | $84M |
Investors
Dawn BiopharmaEIFOLongview VenturesNovo HoldingsPictet GroupSR OneVersant Ventures
Similar companies in biotech
Explore funding flow on EquityFlow →